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Outcomes of endovascular interventions for TASC
II B and C femoropopliteal lesions
Donald T. Baril, MD, Luke K. Marone, MD, Justine Kim, Michael R. Go, MD,
Rabih A. Chaer, MD, and Robert Y. Rhee, MD, Pittsburgh, Pa
Objective: To evaluate outcomes of endovascular interventions on femoropopliteal occlusive disease and determine
predictors of restenosis of Trans Atlantic Inter-Societal Consensus (TASC) II B and C lesions.
Methods:All patients undergoing endovascular interventions for femoropopliteal occlusive disease betweenMay 2003 and
July 2007 were reviewed. Patient demographics, pre- and post-procedure ankle-brachial indices (ABI), and anatomic
factors (including categorization by TASC II classification, lesion length, and runoff vessel status) were analyzed.
Outcomes evaluated included freedom from restenoses, freedom from re-intervention, overall patency, and assisted-
patency.
Results: A total of 237 total limbs were treated during the period reviewed. The study group included 108 TASC B and
32 TASC C limbs in 125 patients (mean age 73.1  10.4 years, male sex: 59%). Seventy-one percent of patients were
Rutherford classification 2/3 while the remaining 29% were Rutherford classification 4/5. Mean follow-up period was
12.7 months (range, 1-52 m). Forty-one (41) limbs experienced restenosis or occlusion at a mean time of 8 months
(range, 1-24 m). Freedom from restenosis/occlusion was 58.9% at 12 months and 47.9% at 24 months. Predictors
of restenosis included a preoperative ABI <0.5 (hazard ratio [HR] 3.05, 95% confidence interval [CI] 1.36-6.86, P 
.007) and hypercholesterolemia (HR 2.42, 95% CI 1.11-5.25, P  .025). Lesion length as a continuous variable (per
centimeter) also correlated with a higher risk of restenosis (HR 1.06, 95% CI 1.00-1.12, P  .057). The overall
assisted-primary and secondary-patency rates were 87% and 94% respectively at 3 years with no significant differences
between TASC B and TASC C limbs.
Conclusion: Endovascular interventions for TASC II B and C lesions are associated with restenosis/occlusion rates that
are at least as good as those of open femoropopliteal bypass surgery from historical, previously published series.
Furthermore, overall assisted-patency rates are excellent, although low preoperative ABIs continue to be associated with
worse outcomes. (J Vasc Surg 2008;48:627-33.)Peripheral artery disease affects nearly 10 million
people in North America and 30% of Americans over the
age of 70.1,2 The superficial femoral artery is highly
susceptible to atherosclerosis disease, which can contrib-
ute to disabling symptoms ranging from intermittent
claudication to limb threatening ischemia. Conservative
treatment strategies including risk factor modification,
smoking cessation, exercise therapy, and pharmacologic
agents have had limited success.3-6 This general failure of
traditional therapy has contributed to a paradigm shift
during the last decade with endovascular treatment for
symptomatic femoropopliteal occlusive disease emerging
as the initial therapy, particularly for short segment
lesions. The recently published Trans Atlantic Inter-
Societal consensus document (TASC II) promotes endo-
vascular techniques including angioplasty and stenting as
first line therapy for femoropopliteal stenotic or occlu-
sive lesions up to 10 cm in length.7 This recommenda-
tion has been made based upon a growing body of
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doi:10.1016/j.jvs.2008.04.059literature which reports 95% technical success in the
treatment of such lesions with very low patient morbid-
ity.8-10 Furthermore, the majority of these procedures
can be performed on an outpatient basis, thus returning
patients to functional status in a shorter time period with
a substantial cost savings.11,12
To date, these techniques have not received over-
whelming support for treating lesions longer than 10 cm.
Initially, this was secondary to low technical success rates
in crossing long segment femoropopliteal occlusive le-
sions. Subsequently, several reports have identified le-
sion length as an independent risk factor for the devel-
opment of restenosis after angioplasty and/or
stenting.13,14 Because of these concerns, it has been the
standard of care to treat more complex (longer lesions)
with surgical bypass. However, advances in endovascular
techniques including utilization of the subintimal tech-
nique for crossing long segment occlusions and selective
use of re-entry devices have significantly contributed to
overcoming these technical limitations, making it possi-
ble to treat even the most complex occlusive lesion with
endovascular techniques.
The purpose of this report is to examine the outcome of
endovascular intervention (angioplasty and stenting) in the
treatment of more complex TASC B and TASC C lesions in
the femoropopliteal location. Endpoints evaluated included:
ankle-brachial index, primary patency, assisted patency, and
predictors of restenosis.
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Patients. All patients undergoing endovascular inter-
ventions for femoropopliteal occlusive disease between
May 2003 and July 2007 were retrospectively identified
from prospectively maintained physician databases. A total
of 237 interventions were identified in 183 patients. Out of
this cohort, 125 patients were identified with either TASC
B (108) of TASC C (32) lesions in 140 limbs. These
patients represent the basis of this report. Fifty-eight ex-
cluded patients had 97 limbs that were either TASC A (82)
or TASC D (15) lesions. Indications for intervention were
either life style limiting claudication (Rutherford 2/3) or
limb salvage (Rutherford 4/5). Therapy for the individual
patient was dictated at the preference of the attending
surgeon based upon clinical presentation, non-invasive lab-
oratory findings, and findings at the time of angiography.
Patient data which were collected were: patient demo-
graphics, co-morbidities, pre- and post-procedure ankle-
brachial indices (ABI), duplex scan velocity data, and the
utilization of adjuvant medical therapy. Additionally, all
angiograms and corresponding angiographic reports were
reviewed to determine TASC II classification of the treated
lesions and to determine the status of the runoff vessels. This
review was completed in a blinded fashion with regards to the
intervention performed and the subsequent outcome.
Procedures. Procedures were performed in either a
fixed-imaging hybrid operating room or in the interven-
tional angiography suite by vascular surgeons. All proce-
dures were performed with patients receiving local anesthe-
sia in addition to conscious sedation. Standard digital
subtraction techniques were employed to maximize image
quality while minimizing use of contrast agent. Patients
with preoperative renal insufficiency (baseline sCr 1.5
mg/dL) were routinely treated peri-procedurally with oral
N-acetylcysteine and intravenous hydration. Arterial access
was performed via the common femoral artery through a
contralateral retrograde approach or an ipsilateral ante-
grade approach using 5F or 6F sheaths. A standard aorto-
gram and unilateral or bilateral runoff was performed uti-
lizing a power injector.
Interventions were performed following the adminis-
tration of systemic heparin (40-100 U/kg). Lesions were
crossed with a 0.035-inch wire. For complete occlusions, a
soft 0.035 inch glide wire (Terumo Medical Corp, Somer-
set, NJ) and a 4/5 Fr glide catheter (Terumo Medical
Corp, Somerset, NJ) were utilized to cross in a subintimal
fashion. When necessary, a re-entry device, Outback LTD
(Cordis Endovascular, Warren, NJ) was employed to gain
access to the flow lumen. Re-entry was confirmed with
contrast injection prior to intervention. Balloon angio-
plasty was subsequently performed with a non-compliant
balloon (various manufacturers). Balloon diameter was se-
lected based on the angiographic measurements of the
non-diseased artery proximal and distal to the lesion. Nom-
inal inflations were maintained for a minimum of one
minute. Stents were implanted following balloon angio-
plasty for the treatment of flow-limiting dissections orresidual stenosis of30% after angioplasty or at the discre-
tion of the operating surgeon. All stents utilized were
nitinol self-expanding stents (various manufacturers).
Whenever multiple stents were utilized, a minimumoverlap
zone of 0.5-1.0 cm was achieved. Access site closure was
performed using manual compression or with the 6 Fr
Angioseal (St. JudeMedical, St. Paul, Minn) device follow-
ing femoral arteriography.
All patients were administered a 300-mg loading dose of
clopidogrel immediately following the procedure and subse-
quently maintained on 75 mg daily for a minimum of 6
months. Patients who had previously been intolerant of clo-
pidogrel secondary to bleeding complications were adminis-
tered 325 mg of aspirin and maintained on 325 mg/day.
Follow-up. Patients were seen in follow-up initially at 1
month, 3 months, and 6 months after their procedure. Patients
were then evaluated at 6-month intervals. Follow-up visits
included an office visit with a physician and noninvasive studies
including ABIs, pulse volume recordings, and complete
arterial duplex ultrasound scan examinations of the treated
limb. Patients who developed recurrent symptoms, evi-
dence of recurrent or novel stenoses on ultrasound, or signif-
icant ABI decreases underwent angiography. Follow-up data
was gathered from hospital visits and in-hospital imaging via
our electronic medical record system in addition to reports of
patients’ clinic visits.
Definitions and classifications. Coronary artery dis-
ease was defined as a history of angina, myocardial infarc-
tion, or prior coronary artery revascularizations. Chronic
renal impairment was defined as a serum creatinine level of
1.5 mg/dL or greater ina patient on permanent dialysis.
Cerebrovascular disease included a history of stroke, tran-
sient ischemic attack, or previous carotid artery revascular-
ization. Hypertension was defined by medication require-
ment to maintain a systolic blood pressure less than 140
mm Hg. Hypercholesterolemia and diabetes were defined
based on patients who had elevated cholesterol levels (ei-
ther total or reduced HDL/LDL ratios) including those
who were on lipid-lowering agents and the use of insulin or
oral hypoglycemics respectively.
The TASC II B lesions were defined as multiple lesions
(stenoses or occlusions)5 cm, single stenosis or occlusion
15 cm not involving the infrageniculate popliteal artery,
single or multiple lesions in the absence of continuous tibial
vessels to improve inflow for a distal bypass, heavily calcified
occlusions 5 cm in length, or a single popliteal stenosis.7
The TASC II C lesions were defined as multiple stenoses or
occlusions totaling 15 cm with or without heavy calcifi-
cation or recurrent stenoses or occlusions that need treat-
ment after two endovascular interventions.
Endovascular procedures were considered technically
successful when all lesions treated had a 20% residual
stenosis on completion of angiography. Primary patency
was defined as the absence of restenosis or occlusion in the
treated arterial segment. Restenosis was defined as either a
return of patients’ symptoms in conjunction with noninva-
sive testing, which confirmed recurrent disease (ABI de-
crease 0.15, dampened pulse volume recordings, or evi-
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velocity 300 cm/sec or ratio 3.0), or based on duplex
scan findings indicative of recurrent disease alone for select
patients who had no clinical symptoms. Occlusion was
defined as a return of the patients’ symptoms in conjunc-
tion with absence or marked decrease in arterial flow on
color duplex scan in the treated vessel or, in asymptomatic
patients, based on duplex scan findings alone. Assisted-
primary patency was achieved via secondary endovascular
interventions to treat restenoses involving the originally
treated arterial segment. Additional procedures to treat
lesions proximal or distal to the initially treated segment
were also considered secondary interventions to achieve
assisted-primary patency. Secondary patency was achieved
utilizing secondary procedures which involved recanalizing
occluded arterial segments.
Statistical analysis. An independent statistician per-
formed all advanced statistical analyses. Freedom from re-
stenoses, freedom from re-intervention, primary patency,
and assisted-patency were calculated using survival curve
analysis. Univariate regression analysis was used to deter-
mine possible pre-procedural and anatomic predictors of re-
stenosis including comorbidities, indications for treatment,
and anatomic factors. Variables with a P-value  .25 on
univariate analysis were then assessed in a multivariate regres-
sion analysis using Cox proportional hazards modeling.
RESULTS
Patientpopulation. During the time period reviewed, a
total of 140 limbs were treated with TASC B (n 108) and
C (n  32) lesions. One-hundred (71%) of these TASC B
or C limbs were Rutherford classification 2/3, while the
remaining forty (29%) were Rutherford classification 4/5.
Of the 40 limbs that were treated for limb salvage, 25 were
for rest pain and 15 were for tissue loss. The mean age was
73.1  10.4 years. A male predominance (60%) was noted
and the typical co-morbid features associated with periph-
eral arterial disease were identified (Table I).
Mean pre-procedural ABI was 0.66  0.21 including
29 (21%) limbs with pre-procedural ABIs 0.5. Ninety-
nine limbs (71%) had two or more infrapopliteal vessels
present on initial angiography. Specifically, 41 limbs had
single-vessel runoff, 48 had two-vessel runoff, and 51 had
three-vessel runoff. Mean lesion length was 11.7 6.3 cm.
Twenty-two (16%) limbs were treated with angioplasty
alone while the remainder underwent angioplasty with
adjunctive stenting. Twenty-three limbs (16%) had con-
comitant procedures to improve inflow or outflow.
Immediate outcomes. Technical success was achieved
in 98% of patients who underwent endovascular treatment
of TASC B and C lesions. There were no peri-procedural
deaths. Immediate complications occurred in three patients
(2%). Two patients developed significant access-related com-
plications: one required a blood transfusion after developing a
large hematoma and the other required ultrasound-guided
thrombin therapy for the treatment of a femoral artery pseu-
doaneurysm. A third patient developed flash pulmonary
edema requiring intubation and a 1-day stay in an intensivecare unit. Ninety percent of patients were treated as outpa-
tients and were discharged on the day of the procedure or
within 23 hours of the procedure.
Follow-up. Mean follow-up length was 12.7  10.4
months (median 10.0 months, range, 1-52 months), ex-
cluding 10 patients who were lost to follow-up. Mean
immediate increase in ABI (measured within 1 month
following intervention) was 0.29  0.21. During the
follow-up period, 41 limbs (29%) experienced restenosis
(36) or occlusions (5) at a mean time of 8.3 months (range,
1-24). Ten of these 41 experienced restenosis or occlusion
within the first three months following their initial inter-
vention. All patients underwent attempted endovascular
salvage at the time of diagnosis of restenosis or occlusion.
Freedom from restenosis/occlusion was 58.9% at 12
months and 47.9% at 24 months for the entire cohort
(Fig 1). The TASC B lesions trended toward higher rates of
freedom from restenosis/occlusion compared to TASC C
lesions at both 12 and 24 months (64.0% vs 46.3% and
49.1% vs 46.3%, P .86); however, it should be noted that
the standard error for the TASC C cohort exceeded 10% at
7.2 months.
Assisted-primary patency rates as maintained by addi-
tional endovascular procedures were 95.8%  1.8% at 6
months, 89.3% 3.3% at 12 months, and 87.1% 3.9% at
24 months (Fig 2). Secondary patency rates as maintained
by additional endovascular procedures were 98.3%  1.1%
at 6 months, 94.0%  2.4% at 12 months, and 94.0% 
2.4% at 24 months (Fig 3). The TASC B lesions trended
toward higher rates of assisted-primary (88.7  4.3% vs
81.9 8.5% at 36months, P .60) and secondary patency
(95.9 2.3% vs 87.1 7.0% at 36 months, P .24) when
compared to TASC C lesions. Six patients (4.3%) went on
to require open revascularizations including 5 femoral to
popliteal artery bypasses and 1 femoral to anterior tibial
artery bypass following failed endovascular salvage at-
Table I. Patient and lesion characteristics
Characteristic %
Male sex 60%
Age 70 69%
Cerebrovascular disease 14%
Chronic renal insufficiency 15%
On hemodialysis 4%
Coronary artery disease 45%
Congestive heart failure 7%
Diabetes mellitus 40%
Hypercholesterolemia 46%
Hypertension 80%
Tobacco use
Prior 69%
Active 24%
TASC B 77%
TASC C 23%
ABI  0.5 21%
2 infrapopliteal runoff vessels 71%
ABI, ankle-brachial indices; TASC,Trans Atlantic Inter-Societal Consensus.tempts. All of these bypasses were patent at last follow-up
Cons
Cons
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amputation during the follow-up period.
Risk factors for restenosis. Significant predictors of
restenosis included a preoperative ABI  0.5 (hazard ratio
[HR] 3.05, 95% confidence interval [CI] 1.36-6.86, P 
.007) and hypercholesterolemia (HR 2.42, 95% CI 1.11-
5.25, P  .025) (Table II). Lesion length as a continuous
variable (per centimeter) also correlated with a higher risk
of restenosis (HR 1.06, 95% CI 1.00-1.12, P  .057).
Furthermore, a pre-procedural ABI 0.5 was associated
with a higher risk of occlusion (HR 6.46, 95% CI 
1.23-33.97, P  .028). The use of angioplasty alone was
not associated with a higher risk of restenosis or occlusion
in either TASC B of TASC C lesions. Additionally, neither
TASC C classification nor greater than or less than two
runoff vessels were associated with a higher risk of resteno-
Fig 1. Survival curve analysis demonstrating freedom fr
endovascular intervention. Trans Atlantic Inter-Societal
Fig 2. Survival curve analysis demonstrating assisted-
endovascular intervention. Trans Atlantic Inter-Societalsis or occlusion.DISCUSSION
With increasing availability of advanced endovascular
techniques and devices to treat femoropopliteal occlusive
disease, a larger number of patients are currently being
treated with these less invasive techniques. However, the
mid-term and long-term results of these endovascular treat-
ments have not been fully elucidated and, thus, therapeutic
approaches to these patients with femoropopliteal occlusive
disease remain somewhat controversial.
The TASC II consensus statement updated the ana-
tomic and morphologic characteristics of femoropopliteal
lesions and redefined the guidelines for therapeutic ap-
proaches to this disease.7 For TASCA lesions, endovascular
therapy was designated as the treatment of choice while
surgical therapy was determined to be the treatment of
stenosis/occlusion of femoropopliteal arteries following
ensus (TASC II).
ry patency rates of femoropopliteal arteries following
ensus (TASC II).om reprimachoice for TASC D lesions. However, for TASC B and C
sus (T
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treatment was less well-defined. Endovascular approaches
are the preferred treatment for type B lesions and surgery is
Fig 3. Survival curve analysis demonstrating secondary
cular intervention. Trans Atlantic Inter-Societal Consen
Table II. Univariate and multivariate analysis of factors
associated with restenosis
Risk factor Hazard ratio 95% CI P-value
Univariate analysis
Age (years) 0.99 0.96-1.02 .65
Age 70 years 0.92 0.44-1.94 .83
Male 1.13 0.55-2.34 .74
CAD 1.45 0.72-2.93 .29
CHF 0.48 0.09-2.52 .38
Claudication 1.41 0.62-3.28 .42
CRI 1.05 0.39-2.86 .92
Dialysis 2.53 0.60-10.66 .21
Current smoker 1.36 0.65-2.87 .41
Previous smoker 1.54 0.65-3.65 .33
Diabetes mellitus 1.01 0.49-2.08 .97
Hypercholesterolemia 1.63 0.80-3.34 .18
Prior CVA 1.22 0.45-3.33 .69
Prior MI 1.82 0.81-4.08 .15
Rutherford 4/5 0.71 0.30-1.65 .42
ABI 0.50 2.59 1.22-5.47 .013
Angioplasty only 1.58 0.62-4.01 .34
Run off 2 1.00 0.44-2.27 .99
Hypertension 0.46 0.22-0.96 .039
TASC C 1.21 0.54-2.71 .64
Lesion length (per cm) 1.05 1.00-1.11 .044
Lesion 10 cm 1.01 0.51-1.98 .98
Multivariate analysis
Hypercholesterolemia 2.42 1.11-5.25 .025
Hypertension 0.41 0.18-0.90 .027
ABI 0.50 3.05 1.36-6.86 .007
Angioplasty only 2.06 0.76-5.55 .15
Lesion length (per cm) 1.06 1.00-1.12 .057
ABI,Ankle-brachial indices;CAD, coronary artery disease;CHF, congestive
heart failure;CI, confidence interval;CRI, chronic renal insufficiency;CVA,
cardiovascular accident; MI, myocardial infarction; TASC, Trans Atlantic
Inter-Societal Consensus.the preferred treatment for good-risk patients with type Clesions. However, the TASC II authors state that when
considering therapy for B and C lesions that the patient’s
co-morbidities, the patient’s preference, and the local op-
erator’s long-term success rates must all be considered. To
date, there has been limited data on outcomes of TASC B
and C lesions treated with endovascular techniques.
The therapeutic goals in the treatment of patients with
intermittent claudication have been to achieve improved
functional status and quality of life. Endovascular interven-
tion offers immediate improvement in functional status
without a prolonged recovery phase as is the case with
surgical bypass. As demonstrated by a review of post-
procedural office notes from our study, immediate subjec-
tive benefit is realized by the patient and contributes greatly
to patient satisfaction. It should be noted that one limita-
tion of our study is that we did not specifically examine
objective measurements of patient satisfaction and func-
tional status. Additionally, maintenance of this benefit re-
quires the commitment (by both the physician and the
patient) to regular follow-up and the informed understand-
ing that there is a high likelihood that additional endovas-
cular procedures may be required to maintain improved
functional status as well as to sustain target vessel revascu-
larization. Indeed, the mean time to recurrent stenosis in
our series of complex TASC II B and C lesions was 8.3
months.
Our report, along with others8-10,15-17 confirms that
endovascular treatment of femoropopliteal occlusive le-
sions may be safely performed and is associated with pa-
tency rates at 2 years which rival patency rates following
surgical bypass based on results from historical data. With
regards to morbidity and mortality, our series had a major
complication rate of 2% and no intervention-associated
mortalities. Furthermore, the majority of patients treated
were discharged home the same day or after a 1-night
hospital stay. Comparatively, complication rates following
cy rates of femoropopliteal arteries following endovas-
ASC II).patensurgical bypass are reported to be as high as 41%.18-20
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hospital stay as well as convalescence until full recovery is
achieved.
In our series of TASC B and C lesions, overall 2-year
assisted patency rate was 93.5% based on life-table analysis.
Although these aremid-term figures, they are comparable if
not better than most series of surgical bypass. It should be
noted that under the TASC II definitions, our series in-
cluded multiple lesions (stenoses or occlusions) 5 cm,
single stenoses or occlusions 15 cm (TASC II B), and
multiple stenotic or occlusive totaling 15 cm (TASC II
C), all lesions that historically were certainly treated with
surgical bypass. Burger et al21 performed a prospective
randomized study of 151 patients comparing saphenous
vein conduits versus polytetrafluorethylene for above knee
bypass. At 2 years, the primary patency was 83% for saphe-
nous vein and 67% for polytetrafluoroethylene while the
secondary patency was 83% for saphenous vein and 77% for
polytetrafluoroethylene. Similarly, Devine et al18 studied
the use of heparin-bonded Dacron or polytetrafluorethyl-
ene for femoropopliteal bypass in a multi-institutional pro-
spective randomized trial and observed secondary patency-
rates of 73% and 55% at 1 and 3 years for heparin-bonded
Dacron and 63% and 48% for PTFE. In a meta-analysis by
Pereira et al,22 secondary-patency rates at 2 years for patients
undergoing surgical bypass for the treatment of claudication
were 85.3% and 86.2% for prosthetic and vein conduits, re-
spectively. In the same meta-analysis, secondary-patency
rates at 2 years for patients undergoing surgical bypass for
the treatment of critical ischemia were 70.1% and 83.7% for
prosthetic and vein conduits.
There has been concern that with increasing applica-
tion of endovascular techniques in complex femoropopli-
teal lesions that later surgical options for revascularization
may be jeopardized. In our study, six patients went on to
have disease progression requiring surgical bypasses and all
grafts remained patent at last follow-up. This data confirms
other studies which have concluded that initial endovascu-
lar therapy for femoropopliteal occlusive disease does not
eliminate the later anatomic suitability and success of sur-
gical bypass.15,23,24
In this study, factors which were associated with a
higher risk of restenosis were: hypercholesterolemia, a pre-
operative ABI 0.5, and longer lesion lengths. Previous
studies have cited hypertension, diabetes mellitus, renal
failure, congestive heart failure, and lesion length to be
associated with predictors of lower patency rates following
angioplasty and stenting of femoropopliteal occlusive le-
sions.13-15,23-27 Although hypercholesterolemia has not
previously been directly correlated with worse outcomes for
lower extremity vascular interventions, there is some evi-
dence that lipid-lowering agents may help to control ath-
erosclerotic disease in the lower extremities.28 Additionally,
the use of statins has been shown to be associated with
higher patency of infrainguinal vein bypasses.29 As impli-
cated by the correlation of restenosis with an ABI0.5 and
longer lesions, more advanced disease also appears to be
associated with worse outcomes following endovasculartreatment of femoropopliteal disease both in our series and
in others.15,23 Of note, hypertension appeared to demon-
strate a protective effect against restenosis, which is con-
trary to previous reports. The exact etiology of this is
unclear and certainly may be a result of sample size given
the overwhelming majority of patients who were hyperten-
sive in our study.
Data frommultiple prospective trials and meta-analyses
have been inconclusive with regards to patency and the
routine use of stent implantation following angioplasty of
femoropopliteal occlusive lesions.9,10,30,31 Our present se-
ries reviewing TASC II B and C lesions did not demon-
strate a higher risk of restenosis with the use of angioplasty
alone. However, it should be noted that these lesions were
treated at the discretion of the operating surgeon and were
not systematically chosen to undergo stenting. Further-
more, this study is limited by the small number of patients
who were treated with angioplasty alone (16%). Clearly
more data on these advanced lesions will be necessary to
determine the impact of routine stenting on long-term
patency.
This study has a number of limitations, the most im-
portant of which is its retrospective nature. Patient selec-
tion and treatment modality were not standardized. In
particular, the use of concomitant stenting along with
angioplasty was performed for specific clinical scenarios,
but, also, at the discretion of the surgeon. Furthermore,
although data has been derived based on survival curve
analysis, the mean and median follow-up time are limited,
and longer-term follow-up will be necessary to determine
the durability of these interventions. Finally, although we
have compared our results to historical results of conven-
tional surgical bypass, this study did not directly compare
results to surgical bypasses performed at our institution
over the contemporaneous time period.
CONCLUSION
Endovascular treatment of TASC II B and C lesions
may be performed safely with minimal morbidity. Mid-
term assisted-patency rates appear to be equal if not higher
than conventional open femoropopliteal bypass surgery
and may be achieved with the use of minimally invasive
endovascular techniques. However, low preoperative ABIs,
hypercholesterolemia, and longer lesions appear to be as-
sociated with higher rates of restenosis. To maintain long-
term patency following endovascular therapy, both patients
and surgeons must be committed to meticulous follow-up
with regular office visits and duplex scan examinations.
Longer-term results will be necessary to further evaluate
the efficacy of endovascular interventions on these ad-
vanced lesions over time in addition to their impact on
future procedures.
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